Research Analysts Set Expectations for ALHC FY2024 Earnings

Alignment Healthcare, Inc. (NASDAQ:ALHC - Free Report) - Stock analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for Alignment Healthcare in a research report issued to clients and investors on Wednesday, October 30th. Leerink Partnrs analyst W. Mayo now expects that the company will post earnings per share of ($0.72) for the year, up from their prior forecast of ($0.76). The consensus estimate for Alignment Healthcare's current full-year earnings is ($0.68) per share. Leerink Partnrs also issued estimates for Alignment Healthcare's Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.19) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.10) EPS, FY2027 earnings at $0.29 EPS and FY2028 earnings at $0.74 EPS.

Several other equities analysts have also recently weighed in on the company. Robert W. Baird lifted their price objective on Alignment Healthcare from $10.00 to $11.00 and gave the company an "outperform" rating in a report on Wednesday, August 14th. Barclays boosted their price target on Alignment Healthcare from $7.00 to $8.00 and gave the stock an "underweight" rating in a research report on Wednesday. UBS Group boosted their price target on Alignment Healthcare from $9.00 to $12.00 and gave the stock a "neutral" rating in a research report on Wednesday. Piper Sandler reaffirmed an "overweight" rating and set a $10.00 price target (up previously from $8.00) on shares of Alignment Healthcare in a research report on Tuesday, August 6th. Finally, KeyCorp started coverage on Alignment Healthcare in a research report on Friday, October 11th. They set a "sector weight" rating on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.33.

Alignment Healthcare Trading Up 4.4 %

ALHC traded up $0.55 during midday trading on Friday, reaching $12.95. 1,423,928 shares of the company were exchanged, compared to its average volume of 1,030,983. The company has a debt-to-equity ratio of 1.82, a quick ratio of 1.61 and a current ratio of 1.60. Alignment Healthcare has a one year low of $4.46 and a one year high of $12.99. The stock has a market capitalization of $2.48 billion, a P/E ratio of -16.82 and a beta of 1.47. The stock's 50-day simple moving average is $10.74 and its 200 day simple moving average is $8.73.

Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.14) EPS for the quarter, hitting analysts' consensus estimates of ($0.14). Alignment Healthcare had a negative return on equity of 108.69% and a negative net margin of 5.84%. The firm had revenue of $692.43 million during the quarter, compared to analyst estimates of $662.11 million. During the same period last year, the company earned ($0.19) earnings per share. The company's revenue was up 51.6% on a year-over-year basis.

Insider Activity

In other news, CFO Robert Thomas Freeman sold 36,197 shares of the company's stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $12.04, for a total transaction of $435,811.88. Following the completion of the sale, the chief financial officer now directly owns 123,429 shares in the company, valued at approximately $1,486,085.16. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CFO Robert Thomas Freeman sold 36,197 shares of the company's stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $12.04, for a total transaction of $435,811.88. Following the completion of the sale, the chief financial officer now directly owns 123,429 shares in the company, valued at $1,486,085.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO John E. Kao sold 90,000 shares of the company's stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $11.33, for a total value of $1,019,700.00. Following the sale, the chief executive officer now owns 2,543,100 shares of the company's stock, valued at approximately $28,813,323. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 354,287 shares of company stock worth $3,964,670. 6.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Alignment Healthcare

Institutional investors and hedge funds have recently bought and sold shares of the company. nVerses Capital LLC acquired a new position in Alignment Healthcare in the 3rd quarter worth about $95,000. Virtu Financial LLC bought a new position in shares of Alignment Healthcare during the first quarter worth about $57,000. Principal Financial Group Inc. bought a new position in shares of Alignment Healthcare during the first quarter worth about $57,000. Creative Planning raised its position in shares of Alignment Healthcare by 20.0% during the third quarter. Creative Planning now owns 12,442 shares of the company's stock worth $147,000 after acquiring an additional 2,072 shares during the last quarter. Finally, Mackenzie Financial Corp raised its position in shares of Alignment Healthcare by 110.0% during the second quarter. Mackenzie Financial Corp now owns 36,526 shares of the company's stock worth $286,000 after acquiring an additional 19,129 shares during the last quarter. Institutional investors and hedge funds own 86.19% of the company's stock.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.